TABLE 2

Aspirin has little effect on 30-day outcomes after surgery: The POISE-2 trial

	Aspirin group	Placebo group	Hazard ratio
Primary outcome (death or myocardial infarction)
Main trial^a	7.0%	7.1%	0.99
In aneurysm surgery	13.7%	9.0%	1.48
In surgery for occlusive disease	15.8%	13.6%	1.16
In nonvascular surgery	6.4%	6.8%	0.95
Secondary outcomes
Vascular occlusive complications
Main trial	0.4%	0.5%	0.82
In aneurysm surgery	0.8%	3.0%	0.25
In surgery for occlusive disease	5.6%	8.8%	0.59
In nonvascular surgery	0.2%	0.2%	1.01
Major or life-threatening bleeding
Main trial	6.3%	5.1%	1.22^b
In aneurysm surgery	6.9%	5.2%	1.45
In surgery for occlusive disease	8.9%	8.0%	1.10
In nonvascular surgery	6.1%	5.0%	1.24^b

↵a N = 10,010, including 265 undergoing aneurysm surgery, 272 undergoing surgery for occlusive disease, and 9,330 undergoing nonvascular surgery.
↵b Statistically significant (P < .05). Data from Biccard et al, reference 7.